SCHEMBL1507276

SCHEMBL1507276

CCSC(=O)OC(C)OC(=O)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.37
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18655565 0.86 TDP1 (0.35) PRKCA
SCHEMBL638234 0.82 PRKCA (0.35) PRKCA
SCHEMBL14566479 0.81 MEN1 (0.35) PRKCAALDH1A1
SCHEMBL18655554 0.81 PRKCA (0.34) PRKCA
SCHEMBL18655549 0.81 PRKCA (0.34) PRKCA
SCHEMBL18655539 0.81 PRKCA (0.34) PRKCA
SCHEMBL14566524 0.80 PRKCA (0.33) PRKCA
SCHEMBL8211801 0.79 PRKCA (0.45) PRKCA
SCHEMBL14632084 0.79 TSHR (0.41) ALDH1A1
SCHEMBL2957024 0.79 PRKCA (0.36) PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 US disclosed
EP-4282867-A1 INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2023-11-29 EP disclosed
CN-105801489-B Cycloalkyl-substituted imidazole derivatives 第一三共株式会社 2019-12-10 CN disclosed
EP-2548871-B1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-07-19 EP disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
US-20140178349-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-26 US disclosed
US-8609710-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-12-17 US disclosed
US-20130230501-A9 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-05 US disclosed
US-20130230501-A9 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-05 US disclosed
US-20130230501-A9 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-05 US disclosed
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-24 US disclosed
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-24 US disclosed
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-24 US disclosed
EP-2548871-A1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-23 EP disclosed
EP-2292590-A2 Prodrugs of 9-aminomethyl tetracycline compounds Paratek Pharmaceuticals, Inc. (US) 2011-03-09 EP disclosed
US-20100249076-A1 PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. (US) 2010-09-30 US disclosed
US-20060287283-A1 Prodrugs of 9-aminomethyl tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2006-12-21 US disclosed
US-20050137174-A1 Prodrugs of 9-aminomethyl tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative F7, F12, TFPI PRKCA 2324/4885ALDH1A1 4432/4885
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF GHSR, GHRHR, NR3C2 PRKCA 4213/4885ALDH1A1 1759/4885
US-20100249076-A1 PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS TET3, TET1, TPMT PRKCA 4113/4885ALDH1A1 3508/4885
US-20050137174-A1 Prodrugs of 9-aminomethyl tetracycline compounds TET3, TET1, TPMT PRKCA 4113/4885ALDH1A1 3508/4885
US-20130230501-A9 Cycloalkyl-Substituted Imidazole Derivative F7, F12, TFPI PRKCA 2324/4885ALDH1A1 4432/4885
US-20060287283-A1 Prodrugs of 9-aminomethyl tetracycline compounds TET3, TET1, TPMT PRKCA 4113/4885ALDH1A1 3508/4885
US-20140178349-A1 Cycloalkyl-Substituted Imidazole Derivative F7, F12, TFPI PRKCA 2324/4885ALDH1A1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.